Freenome (FRNM) vs Veracyte (VCYT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Freenome (FRNM) has outperformed Veracyte (VCYT) over the past year, losing 12.9% versus a loss of 42.9%. Veracyte is the larger company by market cap ($2.03 billion vs $1.04 billion), about 1.9 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | FRNM | VCYT |
|---|---|---|
| Share price | $9.36 | $25.13 |
| Market cap | $1.04B | $2.03B |
| 1-day change | -5.69% | +0.36% |
| YTD return | -28.17% | -40.31% |
| 1-year return | -12.93% | -42.90% |
| 5-year return | — | -39.53% |
| P/E ratio (TTM) | — | 16.32 |
| Forward P/E | — | 16.15 |
| EPS (TTM) | $-1.28 | $1.54 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $517.14M |
| Revenue growth (YoY) | — | +16.01% |
| Net income (latest FY) | $837.47K | $66.35M |
| Gross margin | — | 70.10% |
| Operating margin | — | 11.17% |
| Net margin | — | 12.83% |
| 52-week high | $17.50 | $60.91 |
| 52-week low | $9.28 | $21.91 |
| Distance from 52-week high | -46.51% | -58.74% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +92.31% | +77.48% |
| Average volume | 833.65K | 1.89M |
| Shares outstanding | 111.50M | 80.70M |
| Employees | 363 | 755 |
| Sector | Health Care | Health Care |
| Industry | Medical Specialities | Medical Specialities |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- FRNM has outperformed VCYT by 30.0 percentage points over the past year.
About Freenome
FRNM stock →Freenome, Inc., a biotechnology company, develops blood-based screening tests to detect cancer in the United States. The company offers an early cancer detection platform that integrates multiomics, artificial intelligence, and machine learning to uncover complex biological signals associated with cancer.
Health Care · Medical Specialities · 363 employees
About Veracyte
VCYT stock →Veracyte, Inc. operates as a diagnostics company in the United States and internationally.
Health Care · Medical Specialities · 755 employees
FRNM vs VCYT FAQ
Which is bigger, Freenome or Veracyte?
Veracyte (VCYT) is larger, with a market capitalization of $2.03B compared with $1.04B for Freenome (FRNM).
Which stock has performed better over the past year, FRNM or VCYT?
FRNM returned -12.93% over the past 12 months, compared with -42.90% for VCYT (price return, excluding dividends). Past performance does not predict future results.
Are Freenome and Veracyte in the same industry?
Yes. Both are classified in the Medical Specialities industry within the Health Care sector.